The Impact of a CRM Transition: Q&A with David Rosner

Key Takeaways

• Veeva and Salesforce split creates 50/50 market share
• CRM choice can trigger commercial model redesign
• Avoid lift‑and‑shift; redesign workflows before automation
• AI follow‑up assistants valued by 54% of reps
• Admin burden hampers sales; 69% demand process fixes

Summary

Pharma firms must choose between Veeva and Salesforce CRMs after the vendors split, creating a roughly even market split among the top 20 life‑science companies. Deloitte’s David Rosner says the decision is more than a tech upgrade; it can reshape go‑to‑market strategies and field operations for the next decade. Companies that treat the migration as a simple lift‑and‑shift risk cementing legacy inefficiencies, while those that redesign workflows can reduce administrative burden and unlock AI‑driven assistance. Survey data shows 54% of reps find AI follow‑up tools very useful, and 69% cite broken processes as a sales barrier.

Pulse Analysis

The recent divergence of Veeva and Salesforce into separate CRM platforms has reshaped the technology landscape for life‑science companies. While both solutions were once bundled, the split forces the top twenty pharma players to evaluate distinct ecosystems, pricing models, and integration roadmaps. This market realignment coincides with broader digital transformation pressures, making the timing critical for firms seeking to future‑proof their commercial stack. Analysts note that the 50/50 adoption split reflects not only vendor loyalty but also differing strategic priorities across therapeutic portfolios.

Beyond the headline choice, the real lever for performance lies in how organizations engineer their field workflows around the new platform. Deloitte’s research highlights that AI‑enabled follow‑up assistants are already perceived as valuable by more than half of sales representatives, yet the majority still grapple with cumbersome administrative tasks. By embedding intelligent context and next‑best‑action recommendations directly into the CRM, companies can shift reps’ focus from data entry to value‑added customer interactions, driving higher conversion rates and more precise territory planning.

For C‑suite leaders, the CRM transition is a strategic inflection point rather than a routine IT project. Executives should audit legacy processes, eliminate redundant steps, and define clear governance before automating any function. This disciplined approach prevents the “lift‑and‑shift” trap that locks in outdated operating models. When executed thoughtfully, the new CRM becomes the backbone for a decade‑long commercial transformation, enabling scalable AI adoption, streamlined field operations, and a more agile response to market dynamics.